Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
IGM Biosciences, Inc.
Actuate Therapeutics Inc.
Seagen Inc.
Eli Lilly and Company
Incyte Corporation